Ranbaxy launches “BONISTA-Teriparatide Inj” for Osteoporosis patients

Ranbaxy Laboratories, Country's largest drug maker, has announced the launch of BONISTA- Teriparatide injection (recombinant human parathyroid hormone) for the treatment of Osteoporosis, in collaboration with Virchow Biotech Pvt. Ltd. Hyderabad, India.

Osteoporosis is highly prevalent in India. An estimated 61 million people in India are reported to be affected by it.

Ranbaxy is the first Company to launch this bio generic product in the world. The product has been indigenously researched at Virchow Biotech and developed with and from the Department of Science and Technology, Government of India.

Virchow Biotech, part of the Hyderabad based Rs 600 crore Virchow Group, engages in research, development, manufacture and marketing of a wide range of unique classical biologicals and high value recombinant bio-generie products for serious life-threatening diseases at affordable prices. It also monitors and conducts large multi-centric clinical trials and is a Government of India recognized R&D Centre.

The Osteoporosis segment in India currently has a market size of around Rs 219 crores and grew more than 29% in value terms in 2006-07.